Looking at the filing, I can see this is a Form 10-Q for Protara Therapeutics, Inc. (NASDAQ:TARA) for the quarterly period ended September 30, 2026, filed November 6, 2026. The filing text is cut off before the financial statements are fully shown, but sufficient substantive content exists to proceed.

Protara Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 6, 2026, disclosing operational and financial information for the three and nine months ended September 30, 2026.

Key Highlights

  • Share count: As of November 3, 2026, Protara Therapeutics reported 61,570,351 shares of common stock, par value $0.001 per share, outstanding.
  • Exchange listing: Common stock trades on The Nasdaq Global Market under the ticker TARA (NASDAQ:TARA).
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
  • Product pipeline: According to the filing, the company's product candidates include TARA-002 and Intravenous (IV) Choline Chloride.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.
  • Reporting period: Financial statements cover the three and nine months ended September 30, 2026, compared against the same periods in 2025.

Protara Therapeutics: Q3 2026 Quarterly Filing Details and Pipeline Overview

Protara Therapeutics, Inc., a Delaware-incorporated biopharmaceutical company headquartered at 345 Park Avenue South, 3rd Floor, New York, NY 10010, filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC. The filing carries Commission File Number 001-36694 and covers unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2026, alongside comparative figures for the same periods in 2025. The company's common stock is listed on The Nasdaq Global Market under the symbol TARA, as stated on the cover page of the filing.

According to the filing, Protara Therapeutics is developing two product candidates: TARA-002 and Intravenous (IV) Choline Chloride. The company's forward-looking statements, which are expressly subject to its cautionary language, reference expectations around clinical trial timing, costs, and outcomes, as well as potential market size and commercialization strategy. The filing notes that forward-looking statements "speak only as of the date of this Quarterly Report on Form 10-Q" and that the company disclaims any obligation to publicly release revisions except as required by law.

As of November 3, 2026, the registrant disclosed 61,570,351 shares of common stock outstanding at a par value of $0.001 per share. The company confirmed it has filed all required reports under Section 13 or 15(d) of the Exchange Act during the preceding 12 months and has submitted all required Interactive Data Files electronically. The filing identifies the company as a non-accelerated filer and a smaller reporting company under Rule 12b-2 of the Exchange Act.

What Was Disclosed

Protara Therapeutics submitted its Form 10-Q for the quarter ended September 30, 2026, disclosing 61,570,351 shares outstanding as of November 3, 2026, its non-accelerated and smaller reporting company status, and ongoing development of its TARA-002 and IV Choline Chloride product candidates.